BZT 2312
Alternative Names: BZT-2312; Fast CAR T cellsLatest Information Update: 28 Mar 2024
At a glance
- Originator Shanghai Cell Therapy Group
- Class Antibodies; Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Solid tumours
Most Recent Events
- 07 Mar 2024 Shanghai Cell Therapy Group initiates a phase 0 trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in China (IV) (NCT06327997)